Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 CITY OF HOPE TO EVALUATE PEDMARK  FOR REDUCING OTOTOXICITY IN ADULT MEN WITH STAGE II-III METASTATIC TESTICULAR GERM CELL TUMORS 

FENNEC PHARMACEUTICALS ANNOUNCES INVESTIGATOR-SPONSORED TRIAL TO BE CONDUCTED BY CITY OF HOPE IN METASTATIC TESTICULAR GERM CELL TUMORS

 STUDY, WHICH ENROLLED 27 PATIENTS, MET PRIMARY ENDPOINT WITH A SIGNIFICANT REDUCTION IN HEARING LOSS IN 3-18 YEAR OLD PATIENTS WHO RECEIVED PEDMARK  WHEN COMPARED WITH HISTORICALLY REPORTED RATES OF HEARING LOSS IN PATIENTS RECEIVING CISPLATIN ALONE (16-24% VERSUS 56-63%, RESPECTIVELY) 

FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS

RESEARCH TRIANGLE PARK, N.C., NOV. 26, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON DECEMBER 3, 2025 AT 1:00 P.M. ET, WHICH WILL BE AVAILABLE VIA WEBCAST.

FENNEC PHARMACEUTICALS TO PARTICIPATE IN PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

RESEARCH TRIANGLE PARK, N.C., NOV. 17, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE CLOSING OF ITS UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 5,366,667 COMMON SHARES (WHICH AMOUNT INCLUDES EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL COMMON SHARES) AT A PUBLIC OFFERING PRICE OF $7.50 PER SHARE. FENNEC'S TOTAL GROSS PROCEEDS FROM THE OFFERING (BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND OFFERING EXPENSES) ARE APPROXIMATELY $40,250,000.

FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON SHARES

RESEARCH TRIANGLE PARK, N.C., NOV. 13, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT INTENDS TO ENGAGE IN A NON-BROKERED OFFERING OF ITS COMMON SHARES IN CANADA, AT A PRICE OF US$7.50 PER SHARE, WITH CERTAIN OF ITS EXISTING INSTITUTIONAL SHAREHOLDERS, FOR AGGREGATE GROSS PROCEEDS OF UP TO US$5,025,000. THE OFFERING IS EXPECTED TO CLOSE ON NOVEMBER 17, 2025, SUBJECT TO THE COMPANY ENTERING INTO SUBSCRIPTION AGREEMENTS WITH INVESTORS IN THE OFFERING, IF ANY, AND CERTAIN CUSTOMARY CLOSING CONDITIONS INCLUDING, BUT NOT LIMITED TO, THE RECEIPT OF ALL NECESSARY APPROVALS, INCLUDING APPROVAL FROM THE TORONTO STOCK EXCHANGE (TSX).

FENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA

RESEARCH TRIANGLE PARK, N.C., NOV. 13, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 4,666,667 COMMON SHARES AT A PUBLIC OFFERING PRICE OF $7.50 PER SHARE. IN ADDITION, FENNEC HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 700,000 COMMON SHARES ON THE SAME TERMS AND CONDITIONS. FENNEC ANTICIPATES THE TOTAL GROSS PROCEEDS FROM THE OFFERING (BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND OFFERING EXPENSES) WILL BE APPROXIMATELY $35,000,000, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON NOVEMBER17, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

FENNEC PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON SHARES

RESEARCH TRIANGLE PARK, N.C., NOV. 13, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC) (TSX:FRX) (FENNEC OR THE COMPANY), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL ITS COMMON SHARES IN AN UNDERWRITTEN REGISTERED PUBLIC OFFERING. IN ADDITION, FENNEC INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF ITS COMMON SHARES SOLD IN THE PUBLIC OFFERING.

FENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES

~ ACHIEVED SECOND QUARTER 2025 TOTAL NET REVENUESOF $9.7 MILLION ~ ~ DOUBLE DIGIT NEW ACCOUNTS IN THE SECOND QUARTER OF 2025, INCLUDING NOTABLE QUARTER-OVER-QUARTER GROWTH IN BOTH LARGE COMMUNITY PRACTICES AND ACADEMIC CENTERS, SUPPORTED BY TARGETED SALES STRATEGY AND ENHANCED PATIENT SUPPORT SERVICES FOR PEDMARK  ~ ~ SUCCESSFUL INITIAL UPTAKE OF PEDMARQSI IN THE UNITED KINGDOM AND GERMANY WITH ADDITIONAL EU LAUNCHES PLANNED ~ ~ JAPAN CLINICAL TRIAL (STS-J01) RESULTS EXPECTED IN THE SECOND HALF OF 2025 WITH EVALUATION OF BOTH REGISTRATION AND PARTNERING OR LICENSING EXPECTED THEREAFTER ~ ~ MANAGEMENT TO HOST CONFERENCE CALL TODAY AT8:30 A.M. ET~ RESEARCH TRIANGLE PARK, N.C.

FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., AUG. 11, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 14, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 14, 2025

RESEARCH TRIANGLE PARK, N.C., JUNE 03, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (THE COMPANY) (NASDAQ:FENC) (TSX:FRX) TODAY ANNOUNCED THAT THE NOMINEES LISTED IN THE MANAGEMENT PROXY CIRCULAR DATED APRIL 25, 2025 WERE ELECTED AS DIRECTORS OF THE COMPANY AT THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS HELD IN NEW YORK, NEW YORK ON JUNE 3, 2025.

Fennec Pharmaceuticals Inc.

FENC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Fennec Pharmaceuticals Inc.

FENC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FENC